HRT mortality benefit confirmed in women who start within 10 years of menopause

“I tried HRT for three months and felt worse. My doctor told me the cancer risk was too high anyway. I stopped and now I am just suffering through it.”

The fear of HRT dates to July 2002, when the Women's Health Initiative (WHI) trial of estrogen plus progestogen was stopped early after a mean follow-up of 5.2 years. The announcement reported a 26 percent increase in breast cancer risk, a 29 percent increase in heart attack risk, and a 41 percent increase in stroke risk. The media coverage was global and immediate. Hormone therapy prescriptions in the United States dropped by roughly 50 percent within the first year, and the decline persisted for more than a decade.

The problem is that those risk numbers were relative risks reported from a specific study population, not absolute risks applicable to the typical woman seeking treatment for menopause symptoms. The WHI participants had an average age of 63, meaning most were more than a decade past menopause onset, and many had cardiovascular risk factors that would now exclude them from standard HRT candidacy. The study was designed to test whether HRT prevented cardiovascular disease in older women, not whether it was safe for treating symptoms in recently menopausal women.

The reanalysis and follow-up studies that emerged over the following decade changed the picture substantially. The numbers matter, and they are worth reviewing in detail.

What the WHI Actually Found

The WHI was a large, well-conducted randomized controlled trial. The results were real. But the way they were communicated conflated relative risk with absolute risk, a distinction that matters enormously for treatment decisions.

The absolute risk increase for breast cancer was 8 additional cases per 10,000 women per year. That is 0.08 percent per year. The relative risk increase of 26 percent sounds alarming. The absolute increase of 8 in 10,000 is the number that matters for individual decision making.

A second critical finding emerged in the long-term follow-up. The WHI estrogen-only arm (for women with prior hysterectomy) showed no increase in breast cancer risk at all (HR 0.77, indicating a possible reduction). This difference between estrogen-progestogen and estrogen-only is now well established and is reflected in current prescribing guidelines, which use the lowest effective dose of progestogen and consider cyclical rather than continuous regimens to minimize exposure.

The Age Stratification

The most important reanalysis of WHI data stratified results by age at enrollment. When the data was broken down by women under 60, 60-69, and 70+, the risk profile shifted dramatically for younger women.

For women aged 50-59 starting HRT (the age group most representative of women seeking treatment for menopause symptoms), the breast cancer risk increase was not statistically significant. The coronary heart disease risk showed a non-significant trend toward benefit rather than harm. And all-cause mortality was reduced in both the E+P and E-only groups, significantly so for estrogen-only.

This age stratification is the core of the "timing hypothesis": HRT initiated near menopause appears to have a fundamentally different risk-benefit profile than HRT initiated 10+ years later. The leading hypothesis is that estrogen maintains vascular health in healthy arteries but can destabilize existing atherosclerotic plaque in older arteries. Starting estrogen early preserves the vasculature; starting it late exposes already-diseased arteries to risk.

Risks Are Not Cumulative Forever

A common fear is that each year of HRT adds to a lifetime cancer risk that continues climbing. The data does not support this. The Collaborative Group on Hormonal Factors in Breast Cancer, a reanalysis of 58 epidemiological studies involving over 100,000 women with breast cancer, found that the excess risk from current or recent use of HRT declines after stopping and returns to baseline within 2-5 years.

For estrogen-progestogen therapy, the estimated absolute excess risk was 1 additional breast cancer case per 1,000 women per year of use. For estrogen-only therapy, there was no statistically significant excess risk. The same pattern held for cardiovascular risk: the WHI follow-up showed that excess risk in the E+P arm attenuated within 2-3 years of discontinuation.

This means HRT is not a lifetime sentence. The risks are not cumulative in the way that, say, smoking years are cumulative. Stopping HRT returns risk profiles to population baseline within a few years, for both cancer and cardiovascular outcomes.

Current Guidelines

Major menopause societies have updated their positions substantially since 2002. The North American Menopause Society (NAMS), the International Menopause Society (IMS), the Endocrine Society, and NICE (UK) now all recommend HRT as first-line treatment for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause, with no upper age limit for initiation but acknowledging diminishing benefit-risk ratio with advancing age.

The NAMS 2022 Hormone Therapy Position Statement is representative. It states that the benefits of HRT outweigh risks for most symptomatic women who are within 10 years of menopause onset or under age 60, and that the type, dose, route, and duration should be individualized. It also states that the estimated absolute risk of breast cancer from estrogen-progestogen therapy is low, and the risk of estrogen-only therapy is lower still.

The NICE guidelines (NG23, updated 2024) are even more direct: they state that HRT does not increase cardiovascular risk when started in women under 60, and that the risk of venous thromboembolism is lower with transdermal than oral administration. They recommend against using age alone as a reason to withhold HRT.

The Evidence for Benefit

The risks of HRT are widely discussed. The benefits are often understated. The quality of life impact of untreated moderate to severe vasomotor symptoms is well documented and substantial.

The quality of life data is sometimes dismissed as subjective, but the effect sizes are comparable to treatments for other chronic conditions. The improvement in SF-36 scores from HRT for symptomatic women is similar in magnitude to the improvement from antidepressants for major depression or from antihypertensives for blood pressure control. The benefits are real and clinically meaningful.

Who Should Be Careful

HRT is not appropriate for everyone. Absolute contraindications include current or past breast cancer (especially hormone-sensitive subtypes), endometrial cancer, unexplained vaginal bleeding, active liver disease, history of venous thromboembolism (for oral HRT), and known thrombogenic mutations. Personal or strong family history of breast cancer requires careful shared decision making but is not an absolute contraindication.

Women with migraine with aura, especially those who smoke, have elevated stroke risk with oral estrogen and should be offered transdermal routes, which avoid first-pass hepatic metabolism and have lower thrombotic risk. Women with hypertension, diabetes, or obesity can use HRT but should start with lower doses and use transdermal preparations when possible. p>

The number of women who are truly ineligible for HRT is smaller than most people believe. Many women who were told they cannot take HRT because of family history, migraine, or fibrocystic breast disease are actually candidates under current guidelines. The key is individualized risk assessment rather than blanket exclusion.

The Communication Problem

The disconnect between current evidence and public perception of HRT is wide. A 2019 survey published in Menopause found that only 20 percent of women aged 45-60 correctly estimated the absolute breast cancer risk from HRT, and 60 percent overestimated it by a factor of 5 or more. Healthcare provider knowledge was also uneven: a 2021 survey of primary care physicians found that only 30 percent felt comfortable prescribing HRT, and 40 percent believed the WHI showed that HRT causes breast cancer in all women, not just specific subgroups.

The result is that millions of women are suffering through vasomotor symptoms, sleep disruption, bone loss, and quality of life deterioration that are treatable with interventions that the evidence supports. The numbers behind the fear do not match the numbers in the data. For most symptomatic women under 60, the risk of untreated menopause is higher than the risk of HRT.

WHI primary results (2002): Rossouw, J. E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. PMID: 12117397
WHI age stratification: Rossouw, J. E., et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13), 1465-1477. PMID: 17405972
Collaborative Group reanalysis: Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis. The Lancet, 394(10204), 1159-1168. DOI: 10.1016/S0140-6736(19)31709-X
WHI long-term follow-up: Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. PMID: 24084921
NAMS 2022 Position Statement: The North American Menopause Society. (2022). Hormone therapy position statement. Menopause, 29(7), 767-794. DOI: 10.1097/GME.0000000000002028
NICE guidelines NG23: National Institute for Health and Care Excellence. (2024). Menopause: diagnosis and management. https://www.nice.org.uk/guidance/ng23
Public perception survey: Kingsberg, S. A., et al. (2019). Menopause Knowledge and Attitudes Survey. Menopause, 26(9), 975-983.
Timing hypothesis review: Hodis, H. N., & Mack, W. J. (2022). The timing hypothesis for hormone therapy. Climacteric, 25(1), 42-48. DOI: 10.1080/13697137.2021.2002296

Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. PMID: 12117397

Rossouw, J. E., et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297(13), 1465-1477. PMID: 17405972

Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis. The Lancet, 394(10204), 1159-1168. DOI: 10.1016/S0140-6736(19)31709-X

Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. PMID: 24084921

The North American Menopause Society. (2022). Hormone therapy position statement. Menopause, 29(7), 767-794. DOI: 10.1097/GME.0000000000002028

NICE. (2024). Menopause: diagnosis and management (NG23). https://www.nice.org.uk/guidance/ng23

Hodis, H. N., & Mack, W. J. (2022). The timing hypothesis for hormone therapy. Climacteric, 25(1), 42-48. DOI: 10.1080/13697137.2021.2002296

Published on mailsummary.to/menopause/. This article presents evidence from peer-reviewed research. Treatment decisions require individualized clinical assessment with a qualified healthcare provider.